Chinyu Su

7.6k citations

150 papers · 5.8k indexed · 3 hit papers · h-index 32

Impact in

Genetics top 0.2%
- Inflammatory Bowel Disease
Epidemiology top 0.5%
- Microscopic Colitis

Papers in

Genetics 118
- Inflammatory Bowel Disease 118
Epidemiology 87
- Microscopic Colitis 78

Co-authors: Julián Panés William J. Sandborn Gary R. Lichtenstein Nervin Lawendy Wojciech Niezychowski James D. Lewis Bruce E. Sands Gary S. Friedman
Journals: Gastroenterology (33 papers)The American Journal of Gastroenterology (30 papers)Journal of Crohn s and Colitis (29 papers)Inflammatory Bowel Diseases (13 papers)Clinical Gastroenterology and Hepatology (7 papers)
Partner nations: United States Spain Canada

In The Last Decade

Chinyu Su

147 papers receiving 5.7k citations

Hit Papers

align trajectories log scale

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis 2017 · 1.2k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 New England Journal of Medicine
2012 New England Journal of Medicine
1999 Journal of Clinical Investigation

Peers

Countries citing papers authored by Chinyu Su

Since Specialization

Citations

This map shows the geographic impact of Chinyu Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chinyu Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chinyu Su more than expected).

Fields of papers citing papers by Chinyu Su

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chinyu Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chinyu Su. The network helps show where Chinyu Su may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Chinyu Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Chinyu Su Line = papers co-authored together Chinyu Su links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis Digestive Diseases and Sciences ·Gary R. Lichtenstein, Benjamin L. Cohen, Leonardo Salese, Irene Modesto, Wenjin Wang, Gary Chan, Rudolf Fara, Chinyu Su, Laurent Peyrin‐Biroulet	2023	1
2	Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme Journal of Crohn s and Colitis ·Stefan Schreiber, David T. Rubin, Siew C. Ng, Laurent Peyrin‐Biroulet, Silvio Danese, Irene Modesto, Xiang Guo, Chinyu Su, Kenneth Kwok, Nikita Dilip Vahoniya, J. Sainte-Laudy, Arne Yndestad, Walter Reinisch, Marla C. Dubinsky	2023	17
3	Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs Rheumatology and Therapy ·Kevin Winthrop, Arne Yndestad, Dan Henrohn, Silvio Danese, Sara Marsal, María Galindo-Izquierdo, John Woolcott, Nikita Dilip Vahoniya, Kenneth Kwok, Andrea Shapiro, Thomas V. Jones, نجمه نیسانی سامانی, Chinyu Su, Julián Panés, Stanley Cohen	2022	3
4	Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials Journal of Crohn s and Colitis ·Julián Panés, Séverine Vermeire, Marla C. Dubinsky, Edward V. Loftus, Nervin Lawendy, Wenjin Wang, Leonardo Salese, Chinyu Su, Irene Modesto, Xiang Guo, Jean‐Frédéric Colombel	2021	20
5	Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials Alimentary Pharmacology & Therapeutics ·Brian G. Feagan, Reena Khanna, William J. Sandborn, Séverine Vermeire, Walter Reinisch, Chinyu Su, Leonardo Salese, Haiyun Fan, I Garate Lizarraga, Deborah Woodworth, Wojciech Niezychowski, Bruce E. Sands	2021	11
6	Tu1866 EFFICACY AND SAFETY OF AN ADDITIONAL 8 WEEKS OF TOFACITINIB INDUCTION THERAPY: UPDATED RESULTS OF THE OCTAVE OPEN STUDY FOR TOFACITINIB 8-WEEK INDUCTION NON-RESPONDERS Gastroenterology ·David T. Rubin, Marla C. Dubinsky, Silvio Danese, Rogério Saad-Hossne, Darío Ponce de León, Eric S. Maller, Nervin Lawendy, Kenneth Kwok, Chinyu Su	2020	1
7	Correction to: Characterization of Creatine Kinase Levels in Tofacitinib‑Treated Patients with Ulcerative Colitis: Results from Clinical Trials Digestive Diseases and Sciences ·Remo Panaccione, John D. Isaacs, Lea Ann Chen, Wenjin Wang, Amy Marren, Kenneth Kwok, Lisy Wang, Yin Li-l, Chinyu Su	2020	1
8	Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials Digestive Diseases and Sciences ·Remo Panaccione, John D. Isaacs, Lea Ann Chen, Wenjin Wang, Amy Marren, Kenneth Kwok, Lisy Wang, Gary Chan, Chinyu Su	2020	11
9	Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis Clinical Gastroenterology and Hepatology ·William J. Sandborn, Laurent Peyrin‐Biroulet, Daniel Quirk, Wenjin Wang, Chudy I. Nduaka, Arnab Mukherjee, Chinyu Su, Bruce E. Sands	2020	54
10	Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open Alimentary Pharmacology & Therapeutics ·Bruce E. Sands, Alessandro Armuzzi, John K. Marshall, James O. Lindsay, William J. Sandborn, Silvio Danese, Julián Panés, Brian Bressler, Jean‐Frédéric Colombel, Nervin Lawendy, Eric S. Maller, Haiying Zhang, Gary Chan, Leonardo Salese, Mingeun Kim, Amy Marren, Chinyu Su	2019	65
11	Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis Clinical Gastroenterology and Hepatology ·Stephen B. Hanauer, Remo Panaccione, Silvio Danese, Adam S. Cheifetz, Walter Reinisch, Peter Higgins, Deborah Woodworth, Haiying Zhang, Gary S. Friedman, Nervin Lawendy, Daniel Quirk, Chudy I. Nduaka, Chinyu Su	2018	132
12	Meta‐analysis: factors predicting post‐operative recurrence with placebo therapy in patients with Crohn’s disease Alimentary Pharmacology & Therapeutics ·Christine Jette, Chinyu Su, James D. Lewis, Colleen Brensinger, Gary R. Lichtenstein	2008	69
13	Trends in Hospitalization Rates for Inflammatory Bowel Disease in the United States Clinical Gastroenterology and Hepatology ·Meenakshi Bewtra, Chinyu Su, James D. Lewis	2007	120
14	A Meta-Analysis of the Placebo Rates of Remission and Response in Clinical Trials of Active Ulcerative Colitis Gastroenterology ·Chinyu Su, James D. Lewis, Brittany Goldberg, Colleen Brensinger, Gary R. Lichtenstein	2006	106
15	Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine Gastroenterology Clinics of North America ·Chinyu Su, Gary R. Lichtenstein	2004	53
16	Extraintestinal manifestations of inflammatory bowel disease Gastroenterology Clinics of North America ·Chinyu Su, Thomas Judge, Gary R. Lichtenstein	2002	174
17	Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis The American Journal of Gastroenterology ·Chinyu Su, Bruce Salzberg, James D. Lewis, Julius J. Deren, Asher Kornbluth, David A. Katzka, Robert B. Stein, Heinz-Gerard Justenhoven, Gary R. Lichtenstein	2002	134
18	Recent developments in inflammatory bowel disease Medical Clinics of North America ·Chinyu Su, Gary R. Lichtenstein	2002	14
19	Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits? Digestive and Liver Disease ·Chinyu Su, Robert B. Stein, James D. Lewis, Gary R. Lichtenstein	2000	26
20	A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response Journal of Clinical Investigation ·Chinyu Su, Xiaoming Wen, Shannon T. Bailey, Wen G. Jiang, Shamina M. Rangwala, Sue A. Keilbaugh, Anne Flanigan, Sreekant Murthy, Mitchell A. Lazar, Gary D. Wu Hit paper breakdown →	1999	665

About Chinyu Su

Chinyu Su is a scholar working on Genetics, Epidemiology, Pharmacology, Gastroenterology and Immunology, having authored 150 papers that have together received 5.8k indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (118 papers), Microscopic Colitis (78 papers), Biosimilars and Bioanalytical Methods (24 papers), Diagnosis and treatment of tuberculosis (21 papers), Pharmacological Effects of Natural Compounds (19 papers), Helicobacter pylori-related gastroenterology studies (16 papers), Tuberculosis Research and Epidemiology (14 papers) and Rheumatoid Arthritis Research and Therapies (11 papers). The work is most often cited by research in Genetics (3.8k citations), Epidemiology (2.7k citations), Gastroenterology (378 citations), Rheumatology (864 citations) and Hematology (636 citations). Chinyu Su has collaborated with scholars based in United States, Spain and Canada. Frequent co-authors include Julián Panés, William J. Sandborn, Gary R. Lichtenstein, Nervin Lawendy, Wojciech Niezychowski, James D. Lewis, Bruce E. Sands, Gary S. Friedman, Haiying Zhang and Silvio Danese. Their work appears in journals such as Gastroenterology, The American Journal of Gastroenterology, Journal of Crohn s and Colitis, Inflammatory Bowel Diseases and Clinical Gastroenterology and Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact